Font resize Email Print

Andrei Goga M.D., Ph.D.

Oncogenes and Cell Cycle Control

Andrei Goga M.D., Ph.D.

Our lab seeks to understand how specific oncogenes alter the cell cycle, miRNA and metabolic signaling pathways to drive tumorigenesis.  We study how cancer signaling pathways are activated in breast and liver cancers and hematopoietic malignancies, amongst the most prevalent and deadly forms of human cancer.  We are particularly focused on the MYC oncogene, the downstream pathways it activates, and synthetic-lethal strategies to target MYC ove-rexpressing cancers. Using a variety of model systems we seek to develop anti-cancer therapeutics to selectively inhibit cancer signaling pathways.

Selected publications:

Goga A*, Yang, D, Tward A, Morgan DO and Bishop JM. (2007). Inhibition of Cdk1 as a potential therapy for tumors over-expressing MYC. Nature Medicine. Jul;13(7):820-7.*Corresponding Author

Scott G, Goga A, Bhaumik D, Berger C, Sullivan C, and Benz C. (2007). Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of microRNA miR-125a or miR-125b. J. Biol Chem. 282:1479-86.

Kaye, J.A., Rose, N.C., Goldsworthy, B., Goga, A. and L’Etoile N. (2009). A 3’ UTR Pumilio binding element directs translational activation in olfactory sensory neurons. Neuron Jan 15;61(1):57-70.

Swarbrick A*, Woods S, Shaw A, Balakrishnan A, Phua Y, Chanthery Y, Huskey NE, Lim L, Nguyen A, Ashton L, Sullivan C, Lengyel P, Preiss T, Blelloch R, Weiss W, L’Etoile N, and Goga A*. (2010). miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in neuroblastoma. Nature Medicine October 10. *co-corresponding authors.

Chow EK, Zhang XQ, Chen M, Lam R, Robinson E, Huang H, Osawa E, Goga A, and Ho D. (2011). Nanodiamond drug-delivery platform mediates enhanced in vivo treatment of chemoresistant tumors in mice. Science Translational Medicine Mar 9;3(73):73ra21.

Merrick, K.A., Wohlbold, L., Zhang, C., Allen, J.J., Horiuchi, D., Huskey, N.E., Goga, A., Shokat, K.M., and Fisher, R.P. (2011). Switching cdk2 on or off with small molecules to reveal requirements in human cell proliferation. Molecular Cell. 42:624-636.

Hu, S., Balakrishnan, A., Bok, R.A., Anderton, B., Larson, P.E.Z., Nelson, S.J., Vigneron, D.B., and Goga, A. (2011). 13C-Pyruvate Imaging Reveals Alterations in Glycolysis that Precede c-Myc-Induced Tumor Formation and Regression. Cell Metabolism. July;14:1-12.

Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A. (2012). Cyclin-dependent kinase inhibition induces synthetic-lethality in triple-negative breast cancers via the MYC oncogene pathway. Journal of Experimental Medicine 2012 Apr 9;209(4):679-96. Epub 2012 Mar 19.

Horiuchi D, E Huskey N, Kusdra L, Wohlbold L, Merrick KA, Zhang C, Creasman KJ, Shokat KM, Fisher RP, Goga A. (2012). Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways. Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):E1019-27. Epub 2012 Apr 3. PMID: 22474407